Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes
- PMID: 11571569
- DOI: 10.1038/sj.gt.3301529
Quantitative comparison of expression with adeno-associated virus (AAV-2) brain-specific gene cassettes
Abstract
This study compared a range of mammalian CNS expression cassettes in recombinant adeno-associated virus (AAV-2) vectors using strong endogenous promoter sequences, with or without a strong post-regulatory element and polyadenylation signal. Changes in these elements led to transgene expression varying by over three orders of magnitude. In experiments conducted in primary cell culture and in >100 stereotactically injected rats, we observed highly efficient and stable (>15 months) gene expression in neurons and limited expression in glia; the highest expression occurred with endogenous, nonviral promoters such as neuron-specific enolase and beta-actin. The packaging size of AAV-2 was maximized at 5.7 kb without impairing gene expression, as judged by direct comparison with a number of smaller AAV-2 constructs. The genomic insert size and titer were confirmed by Southern blot and quantitative PCR, and infectivity was tested by particle titer using ELISA with a conformation-dependent epitope that requires the full intact capsid. A packaging and purification protocol we describe allows for high-titer, high-capacity AAV-2 vectors that can transduce over 2 x 10(5) neurons in vivo per microliter of vector, using the strongest expression cassette.
Similar articles
-
Improved neuronal transgene expression from an AAV-2 vector with a hybrid CMV enhancer/PDGF-beta promoter.J Gene Med. 2005 Jul;7(7):945-55. doi: 10.1002/jgm.742. J Gene Med. 2005. PMID: 15756650
-
Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors.Cardiovasc Res. 2006 Apr 1;70(1):70-8. doi: 10.1016/j.cardiores.2005.12.017. Epub 2006 Jan 31. Cardiovasc Res. 2006. PMID: 16448634
-
Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector.Gene Ther. 2007 Jul;14(14):1078-91. doi: 10.1038/sj.gt.3302960. Epub 2007 Apr 26. Gene Ther. 2007. PMID: 17460718
-
Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo.Exp Physiol. 2005 Jan;90(1):53-9. doi: 10.1113/expphysiol.2004.028159. Epub 2004 Nov 12. Exp Physiol. 2005. PMID: 15542619 Review.
-
Gene therapy progress and prospects--vectorology: design and production of expression cassettes in AAV vectors.Gene Ther. 2006 May;13(10):805-13. doi: 10.1038/sj.gt.3302724. Gene Ther. 2006. PMID: 16453010 Review.
Cited by
-
Targeted CNS Delivery Using Human MiniPromoters and Demonstrated Compatibility with Adeno-Associated Viral Vectors.Mol Ther Methods Clin Dev. 2014 Jan 8;1:5. doi: 10.1038/mtm.2013.5. Mol Ther Methods Clin Dev. 2014. PMID: 24761428 Free PMC article.
-
Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice.Mol Neurodegener. 2016 Sep 6;11(1):64. doi: 10.1186/s13024-016-0128-x. Mol Neurodegener. 2016. PMID: 27600816 Free PMC article.
-
Viral expression cassette elements to enhance transgene target specificity and expression in gene therapy.Discov Med. 2015 Jan;19(102):49-57. Discov Med. 2015. PMID: 25636961 Free PMC article. Review.
-
No evidence from complementary data sources of a direct glutamatergic projection from the mouse anterior cingulate area to the hippocampal formation.Elife. 2023 Aug 7;12:e77364. doi: 10.7554/eLife.77364. Elife. 2023. PMID: 37545394 Free PMC article.
-
Targeting Homer genes using adeno-associated viral vector: lessons learned from behavioural and neurochemical studies.Behav Pharmacol. 2008 Sep;19(5-6):485-500. doi: 10.1097/FBP.0b013e32830c369f. Behav Pharmacol. 2008. PMID: 18690104 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical